U.S. Temporarily Blocks New Home Health Providers from Medicare Enrollment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy UNH?
Source: seekingalpha
- New Medicare Regulations: The U.S. government plans to temporarily block new home health and hospice providers from enrolling in Medicare on Wednesday, reflecting a stringent regulatory approach to combat fraud linked to government-backed healthcare programs.
- Nationwide Moratorium: This nationwide pause aims to address healthcare scams, particularly those affecting Medicare, and is expected to enhance transparency and compliance within the healthcare service sector.
- Anti-Fraud Task Force Actions: Vice President JD Vance's anti-fraud task force will announce several policy changes, emphasizing the crackdown on large-scale fraud, which aims to protect the interests of the American public and demonstrates a zero-tolerance stance towards healthcare fraud.
- Industry-Wide Impact: This move could significantly affect major home health and hospice providers, including BrightSpring Health Services and UnitedHealth, prompting companies within the industry to strengthen compliance measures in response to the new regulatory environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 396.390
Low
330.00
Averages
397.82
High
444.00
Current: 396.390
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health provides comprehensive and patient-centered care, addressing the physical, mental, and social well-being. Optum Health delivers primary, specialty and surgical care and helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Significant Stock Fluctuation: UnitedHealth Group's stock price dropped from $336 to $259 at the beginning of 2023, but rebounded by over 47% to around $381 by May 11, indicating a gradual recovery after volatility.
- Q1 Performance Improvement: In Q1 2023, UnitedHealth's revenue increased by 2% year-over-year to $111.7 billion, with earnings per share exceeding expectations at $6.90 and adjusted EPS at $7.23, suggesting a turnaround after leadership upheaval and rising costs.
- Impact of Medicare Advantage: While Medicare Advantage provides revenue, payment rates have not kept pace with rising costs, leading UnitedHealth to cut 1.3 million members in 2026 to improve margins and ensure long-term sustainability.
- Investor Confidence Restoration: Despite facing regulatory challenges like an antitrust investigation, UnitedHealth's dividend yield of approximately 2.3% attracts long-term investors, making the current stock price appealing for buying or holding.
See More
- New Pricing Model: UnitedHealth's pharmacy benefits division, Optum Rx, has introduced a new pharmacy care model that will charge clients a per-member monthly fee, set to launch in 2027, aimed at addressing transparency issues and eliminating spread pricing in traditional PBM models.
- Enhanced Transparency: This new model will bring greater clarity to Optum Rx's fees, including charges from its group purchasing organization, designed to fully align incentives with patients and plan sponsors, thereby improving predictability and affordability in pharmacy care.
- Addressing Drug Price Criticism: The pricing structure builds on several initiatives by Optum Rx to enhance affordability across the U.S. healthcare system, particularly in response to criticism regarding its role in rising U.S. drug prices.
- Future Plans: UnitedHealth plans to pass through all rebate discounts negotiated with drugmakers to clients by January 1, 2028, following an agreement made in January 2025, further strengthening its competitive position in the pharmacy care market.
See More
- Strong Q1 Performance: Major U.S. health insurers, including UnitedHealth Group and Cigna, reported first-quarter results exceeding analysts' expectations, indicating improved cost management capabilities despite industry pressures that have seen the S&P managed care index drop over 12% since July 2023.
- Stabilizing Medical Costs: Analysts noted that while medical costs have continued to rise in government-sponsored health plans, recent performances suggest that cost trends may be stabilizing, with potential for further positive earnings estimate revisions reflecting improving fundamentals in the industry.
- Upcoming Quarter Challenges: Analysts caution that the second quarter typically serves as a test for health insurers, with historical data indicating that claims may surprise in May, prompting investors to closely monitor the upcoming months for financial performance.
- Positive Market Reaction: Despite seasonal factors impacting costs, analysts maintain an optimistic view on the industry's core strength, suggesting that the improvement in medical costs may be sustainable rather than a temporary occurrence, indicating a gradual enhancement of the industry's fundamentals.
See More
- New High Achievement: UnitedHealth Group reached a 52-week high of $404.14 in Wednesday trading, indicating strong market confidence in its future growth prospects.
- Robust Growth Momentum: The stock has surged approximately 30% over the past month and about 21% year-to-date, demonstrating the company's strong performance in the health insurance sector and positive investor sentiment.
- Earnings Beat Impact: Since late April, UnitedHealth's stock has performed well, driven by a Q1 earnings beat and raised guidance, which further solidifies its market position and attractiveness to investors.
- Market Recovery Context: Despite experiencing a selloff in January due to disappointing Q4 2025 earnings and a poor Medicare Advantage rate proposal, the company has rebounded, showcasing its resilience and adaptability in the market.
See More
- New Medicare Regulations: The U.S. government plans to temporarily block new home health and hospice providers from enrolling in Medicare on Wednesday, reflecting a stringent regulatory approach to combat fraud linked to government-backed healthcare programs.
- Nationwide Moratorium: This nationwide pause aims to address healthcare scams, particularly those affecting Medicare, and is expected to enhance transparency and compliance within the healthcare service sector.
- Anti-Fraud Task Force Actions: Vice President JD Vance's anti-fraud task force will announce several policy changes, emphasizing the crackdown on large-scale fraud, which aims to protect the interests of the American public and demonstrates a zero-tolerance stance towards healthcare fraud.
- Industry-Wide Impact: This move could significantly affect major home health and hospice providers, including BrightSpring Health Services and UnitedHealth, prompting companies within the industry to strengthen compliance measures in response to the new regulatory environment.
See More
- IPO Valuation Outlook: SpaceX plans to go public this year with a target valuation of $1.75 trillion, which would make it the largest IPO in history, yet this implies a staggering 95 times its projected 2025 revenue of $18.5 billion, leading to mixed market expectations regarding its future growth.
- Market Competition and Profitability: While SpaceX shows potential in expanding its Starlink satellite network and launching Falcon rockets, concerns about its profitability are rising, especially under pressure from smaller competitors, prompting investors to approach with caution.
- Heartflow Growth Potential: Heartflow went public at $19 per share in August 2025 and is currently trading around $29, with a 40% revenue increase in 2025 and an expected 24%-26% growth in 2026, indicating strong growth potential in the non-invasive cardiac diagnostics sector.
- Neptune Insurance Market Positioning: Neptune Insurance focuses on flood insurance, achieving a 34% revenue increase in 2025 and expecting a 22% growth in 2026, leveraging AI and geospatial data to automate underwriting processes and meet the urgent demand for customized flood insurance solutions.
See More











